Why it was included in the FDA ban Melanotan II was banned for reported adverse effects like melanoma skin cancers, posterior reversible encephalopathy syndrome (a seizure and headache disorder), sympathomimetic toxidrome (symptoms of poisoning), and priapism (dangerous, prolonged erections)
Dual GIP/GLP-1 agonists now represent the highest-revenue growth segment in the GLP-1 weight loss drug market at 18.4% CAGR , with tirzepatide generating USD 18.3 billion in 2025 revenue through Zepbound and Mounjaro surpassing Eli Lillys entire insulin franchise within two years of commercial launch
Kristin serves as a contributing writer for TODAY.com, Eating Well Magazine, Costco Connection , and Cleveland Clinic Health Essentials. Disclosures: Jonathan Clinthorne, PhD, has the following relevant disclosure to report: he is an employee of Simply Good Foods USA, Inc
Table 1 presents the study cohorts baseline demographic, clinical, and medication-related characteristics
Heres why: Preventing Under-Eating: Some GLP-1 users find their appetite is so blunted that they barely feel like eating at all
The studies cited here refer to ingredients, not the product itself
